Symbiotec Pharmalab Receives US FDA VAI Status

Date: September 29, 2026

Regulatory Compliance Update

Symbiotec Pharmalab Limited has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility in Pithampur (SEZ), Madhya Pradesh, India. The EIR was issued with a Voluntary Action Indicated (VAI) status classification.

The U.S. FDA inspection was conducted at the Company's manufacturing facility at Pithampur from August 10, 2026 to August 14, 2026.

The document serves as a regulatory compliance disclosure to the stock exchanges (BSE Limited and National Stock Exchange of India Ltd.) for information and records purposes.